Uptake of Tritium Labelled Mepacrine by Tumours
Author Information
Author(s): J. M. Young, F. Wild, I. Simon-Reuss
Primary Institution: University of Cambridge
Hypothesis
Can mepacrine be used as a carrier for tritium to selectively irradiate tumours?
Conclusion
Mepacrine does not show selective uptake in tumours, making it unlikely to be effective for targeted radiation therapy.
Supporting Evidence
- Normal mepacrine shows limited carcinostatic activity.
- Previous studies indicated mepacrine could be useful for controlling neoplastic effusions.
- High concentrations of mepacrine were found in other tissues compared to tumours.
- Autoradiography showed no uptake of tritium in HeLa cells or Ehrlich ascites tumour cells.
- Variability in tritium distribution was noted across different tissues.
Takeaway
The study looked at how a special drug called mepacrine behaves in tumours, but it turns out it doesn't go into the tumours as hoped.
Methodology
Rats with Walker 256 carcinoma were injected with tritiated mepacrine, and the distribution of tritium in various tissues was measured over time.
Limitations
The study did not confirm selective uptake of tritium in tumours and showed variability in tissue distribution.
Participant Demographics
Rats bearing Walker 256 carcinoma.
Want to read the original?
Access the complete publication on the publisher's website